Sign In
Buy RLYB
$16.07
-0.160 (-0.99%)
At Close: Jun 03, 2026
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati
3 Sorry Biotech Stocks to Sell in May While You Still Can
07:00am, Friday, 31'st May 2024
Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech
3 Biotech Stocks to Sell in May Before They Crash & Burn
06:30am, Friday, 10'th May 2024
Although 5% up over one year, the S&P Biotechnology Select Industry Index is down .22% year-to-date. This seems to be a normalization period.
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
08:00am, Tuesday, 07'th May 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
04:01pm, Wednesday, 17'th Apr 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
11:26am, Friday, 12'th Apr 2024
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Rallybio partners with J&J to advance therapies targeting rare fetal disease
11:32am, Thursday, 11'th Apr 2024
Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thrombo
Why Is Rallybio (RLYB) Stock Up 93% Today?
07:43am, Thursday, 11'th Apr 2024
Rallybio (NASDAQ: RLYB ) stock is rocketing higher on Thursday after announcing a collaboration with Johnson & Johnson (NYSE: JNJ ). Rallybio is receiving support from Johnson & Johnson for the dev
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
08:00am, Tuesday, 12'th Mar 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
08:00am, Monday, 26'th Feb 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
08:00am, Thursday, 04'th Jan 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcut
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study fo
